ClinicalTrials.gg
Active, not recruitingNCT02427451Updated Jun 15, 2026Results posted

Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia

A Phase 1/2 interventional study of Bcl-2 Inhibitor GDC-0199 and Obinutuzumab in Chronic Lymphocytic Leukemia and Refractory Chronic Lymphocytic Leukemia, sponsored by Kerry Rogers. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Kerry Rogers · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
87
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell — 21 open to participants now, 42 under way, 8 of them phase 3. venetoclax · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
28th of 69
87 · median 72
Started
2015
the only one that year
Phase 1/2
3 of 69
1 open now
Primary completion
2021-12
later than 2 of 41 live
Registered
11th of 69
by date
Lead sponsor
4 of 69
Kerry Rogers

Among the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 28th largest by enrollment, is the only one that started in 2015, is one of 3 in phase 1/2, reaches primary completion later than 2 of the 41 other live ones, and was the 11th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

21 of the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This phase Ib/II trial studies the best dose and safety of Bcl-2 inhibitor GDC-0199 in combination with obinutuzumab and ibrutinib and to see how well they work in treating patients with chronic lymphocytic leukemia that has returned (relapsed), does not respond to treatment (refractory), or is previously untreated. Bcl-2 inhibitor GDC-0199 and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as obinutuzumab, may block cancer growth in different ways by targeting certain cells. Giving Bcl-2 inhibitor GDC-0199 together with obinutuzumab and ibrutinib may be a better treatment for chronic lymphocytic leukemia.

Read the detailed description

PRIMARY OBJECTIVES:

I. To identify the dose of venetoclax (Bcl-2 inhibitor GDC-0199) that can be safely administered in combination with obinutuzumab and ibrutinib for the treatment of relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL).

II. To evaluate the feasibility, safety, and tolerability of venetoclax in combination with obinutuzumab and ibrutinib in patients with relapsed/refractory or previously untreated CLL.

III. To determine the minimal residual disease (MRD)-negative complete response (CR) rate after 12 cycles of treatment with venetoclax in combination with obinutuzumab and ibrutinib in patients with relapsed/refractory or previously untreated CLL.

SECONDARY OBJECTIVES:

I. To determine the overall response rate (ORR) and complete response rate (CR) of venetoclax in combination with obinutuzumab and ibrutinib in patients with relapsed/refractory or previously untreated patients with CLL.

II. To estimate progression free survival (PFS) after treatment with venetoclax in combination with obinutuzumab and ibrutinib in patients with relapsed/refractory or previously untreated patients with CLL.

III. To conduct pharmacokinetic and pharmacodynamic studies of venetoclax in combination with obinutuzumab and ibrutinib in patients with relapsed/refractory or previously untreated patients with CLL.

IV. To examine pre-treatment and serial biomarkers associated with response and mechanisms of resistance to venetoclax, obinutuzumab and ibrutinib when given in combination for relapsed/refractory or previously untreated patients with CLL.

OUTLINE: This is a phase Ib, dose-escalation study of Bcl-2 inhibitor GDC-0199 followed by a phase II study.

Patients receive obinutuzumab intravenously (IV) on day 1 (days 1, 2, 8, and 15 for course 1 only) every 28 days for up to 8 courses. Beginning in course 2, patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Beginning in course 3, patients receive Bcl-2 inhibitor GDC-0199 PO QD on days 1-28. Treatment repeats every 28 days for up to 14 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 4 and 8 weeks, every 3 months for 2 years, and then every 6 months thereafter.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Refractory Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of CLL meeting criteria established in the World Health Organization (WHO) classification of hematologic disorders
  • (ECOG) performance status =\< 1
  • CLL patients must meet the following requirements:

    • Received at least 1 prior therapy
    • Require treatment in the opinion of the investigator
    • Relapsed patients must have developed progressive disease following a response to a prior therapy
    • Refractory patients must have failed to respond or relapsed within 6 months to the last prior therapy
  • Treatment-naïve CLL patients must meet the following requirements (Phase II only):

    • Symptomatic disease as defined by International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria
    • Received no prior chemotherapy, immunotherapy, or targeted therapy for the treatment of CLL with the exceptions of palliative loco-regional radiotherapy and for symptom control
  • >= 8 g/dL
  • (ANC) >= 1000/mm\^3
  • >= 40,000/mm\^3
  • (PT)/partial thromboplastin time (PTT) =\< 1.5 x (ULN)
  • Total =\< 1.5 x ULN (excepting Gilbert's syndrome)
  • (AST) and alanine aminotransferase (ALT) =\< 2.5 × ULN
  • Serum creatinine \< 2.0 mg/dL or (Cockcroft) >= 50 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal
  • Female patients must be surgically sterile, (for at least 1 year), or have negative results from a pregnancy test performed as follows:

    • At screening, on a serum sample obtained within 14 days prior to the first study drug administration, and
    • Prior to dosing, on a urine sample obtained on day 1 of treatment if it has been > 7 days since obtaining the serum pregnancy test result
  • All female patients not surgically sterile or post-menopausal (for at least 1 year) and non-vasectomized male patients must practice at least one of the following methods of :

    • Total abstinence from sexual intercourse (minimum one complete menstrual cycle)
    • A vasectomized partner
    • Hormonal contraceptives for at least 2 months prior to day 1 of treatment
    • Double-barrier method
  • Non-vasectomized male patients must practice at least one of the following methods of birth control throughout the duration of study participation and for at least 3 months after study treatment:

    • A partner who is surgically sterile or postmenopausal (for at least 1 year) or who is taking hormonal contraceptives (oral, parenteral, vaginal ring, or transdermal) for at least 3 months prior to study drug administration
    • Total abstinence from sexual intercourse
    • Double-barrier method (condom, diaphragm or cervical cup with spermicidal, contraceptive sponge, jellies, or cream)
  • Ability to understand and the willingness to sign a written document

Exclusion criteria

Exclusion Criteria:

  • Patients who have had chemotherapy, immunotherapy, radiotherapy, or therapy within 28 days prior to entering the study or those who have not recovered from adverse events due to agents administered more than 28 days earlier; for control of disease related symptoms are permitted
  • Patients who are receiving any other investigational agents
  • Uncontrolled hemolytic anemia or thrombocytopenia
  • Active Richter's transformation
  • Known active involvement of the central nervous system by lymphoma or leukemia
  • Patients who require warfarin anticoagulation or who have received warfarin or equivalent vitamin K antagonists =\< 7 days prior to treatment day 1; patients may be eligible if able to be taken off warfarin and started on an alternative anticoagulant
  • Received potent cytochrome P450 3A4 () inhibitors (such as fluconazole, ketoconazole, and clarithromycin) within 7 days prior to the first dose of study treatment
  • Received potent CYP3A4 inducers (such as rifampin, carbamazepine, phenytoin, St. John's wort) within 7 days prior to the first dose of study treatment
  • Consumed grapefruit or grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of study treatment
  • History of a prior significant toxicity, other than thrombocytopenia, from another Bcl-2 family protein inhibitor
  • Known cysteine-481 Bruton's tyrosine kinase (BTK) mutation or CLL to or progressed during ibrutinib or other Cys-481 binding BTK inhibitor treatment
  • Known infection with the (HIV) virus
  • A cardiovascular disability status of class >= 2, defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea, or angina pain
  • Positive hepatitis serology:

    • virus (HBV): patients with positive serology for hepatitis B defined as positivity for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (anti-HBc); patients who are positive for anti-HBc may be considered for inclusion in the study on a case-by-case basis if they are hepatitis B viral deoxyribonucleic acid (DNA) negative and are willing to undergo ongoing HBV DNA testing by real-time polymerase chain reaction (PCR); patients with positive serology may be referred to a hepatologist or gastroenterologist for appropriate monitoring and management

      • Patients with positive HBSAg consistent with prior vaccination to HBV (i.e., anti-HBs+, anti-HBc-) may participate
      • Patients suspected to have false positive serologic studies because of IV immunoglobulin administration are potentially eligible after negative PCR studies for viral DNA/ribonucleic acid (RNA) and discussion with the principal investigator
    • (HCV): patients with positive hepatitis C serology unless HCV RNA is confirmed negative and may be considered for inclusion in the study on a case-by-case basis (e.g., patients with negative viral load after HCV-specific treatment)
  • History of severe (defined as grade 4 and/or requiring permanent discontinuation of prior antibody therapy) allergic or anaphylactic reactions to human, humanized, chimeric, or murine monoclonal antibodies
  • Patients who received a live viral vaccination within 6 months prior to the first dose of study drug
  • A female patient who is pregnant or breast-feeding
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • History of other active other than CLL within the past 3 years prior to study entry, with the exception of:

    • Adequately treated in situ carcinoma or the cervix uteri or breast
    • Basal cell or localized squamous cell carcinoma of the skin
    • Previous malignancy confirmed and surgically resected (or treated with other modalities) with curative intent or without relapse for >= 2 years
  • Vaccination with a \< 28 days prior to the start of treatment
  • Inability to swallow capsules or tablets, or disease significantly affecting gastrointestinal function and/or inhibiting small intestine absorption (malabsorption syndrome, resection of the small bowel, poorly controlled inflammatory bowel disease, etc.)
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Treatment (obinutuzumab, ibrutinib, Bcl-2 inhibitor GDC-0199)

    Patients receive obinutuzumab IV on day 1 (days 1, 2, 8, and 15 for course 1 only) every 28 days for up to 8 courses. Beginning in course 2, patients receive ibrutinib PO QD on days 1-28. Beginning in course 3, patients receive Bcl-2 inhibitor GDC-0199 PO QD on days 1-28. Treatment repeats every 28 days for up to 14 courses in the absence of disease progression or unacceptable toxicity.

    Drug: Bcl-2 Inhibitor GDC-0199 · Biological: Obinutuzumab · Drug: Ibrutinib · Other: Pharmacological Study · Other: Laboratory Biomarker Analysis · Other: Quality-of-Life Assessment

Interventions

  • DrugVenetoclaxStudies of VenetoclaxVenetoclax pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given PO

    Also known as: ABT-0199, ABT-199, GDC-0199, RG7601

  • BiologicalObinutuzumab

    Given IV

    Also known as: Anti-CD20 Monoclonal Antibody R7159, GA101, Gazyva, R7159, RO 5072759

  • Given PO

    Also known as: BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765

  • OtherPharmacological Study

    Correlative studies

    Also known as: pharmacological studies

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose of Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib (Phase Ib)

    Time frame: 28 days (course 3)

  2. Minimal Residual Disease (MRD)-Complete Response (CR) Defined by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Criteria (Phase II)

    Assessments of MRD will be used in patients classified as CR to further evaluate their status as disease-free and if this further impacts their ability to remain progression-free and alive. MRD will be determined by high sensitivity 4 color flow cytometric analysis of the bone marrow using validated panels.

    Time frame: Up to 8 weeks post-treatment

Secondary outcomes

  1. Number of Adverse Events Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0

    For all patients who receive at least one day of treatment, toxicities will be tabulated by type and grade and displayed in summary form. Serious adverse events are listed with "(SAE)" after the event name.

    Time frame: Up to 4 years

  2. Number of Courses Started/Completed

    May be summarized.

    Time frame: Up to 14 months

  3. Number of Patients Who Reach the Target Dose of Bcl-2 Inhibitor GDC-0199

    May be summarized.

    Time frame: Up to 14 months

  4. Number of Patients Requiring Dose Reductions

    May be summarized.

    Time frame: Up to 14 months

  5. Reason for Going Off Treatment

    May be summarized.

    Time frame: Up to 14 months

  6. Overall Response Rate

    Overall response rate will be reported for all evaluable patients in the phase II setting, within and potentially across cohorts, assuming a binomial distribution.

    Time frame: Up to 4 years

  7. Progression-free Survival (PFS)

    Will be summarized by the Kaplan-Meier method for each of the phase II cohorts.

    Time frame: Time from first treatment date until the date of progression or death, whichever occurs first, assessed up to 8 years

  8. Emotional Distress Assessment

    Validated instruments will be administered serially to assess longitudinal changes in measures of health related quality of life using 36-Item Short Form Survey (SF-36) Mental Component Scale (MCS) T-scores for each time point with pairwise comparison p-values. Scores on the SF-36 scale range from 0 to 100, with higher scores indicating better mental health. Scores for the MCS are standardized using U.S. general population norms with summary scores set relative to a t-score mean of 50 and a standard deviation of 10.

    Time frame: Cycle 1 day 1, cycle 2 day 1, cycle 3 day 1, cycle 6 day 1 and cycle 12 day 1

  9. Health Related Quality of Life

    Validated instruments will be administered serially to assess longitudinal changes in measures of health related quality of life using 36-Item Short Form Survey (SF-36) Physical Component Scale (PCS) T-scores for each time point with pairwise comparison p-values. Scores on the SF-36 scale range from 0 to 100, with higher scores indicating better physical health. Scores for the PCS are standardized using U.S. general population norms with summary scores set relative to a t-score mean of 50 and a standard deviation of 10.

    Time frame: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 6 Day 1, and Cycle 12 Day 1 (each cycle is 28 days)

  10. Serial Assessment of Immune Effector Cell Number and Function.

    Peripheral blood immunophenotyping will be used to enumerate immune effector cells (counts and percentages of T-, and Natural Killer (NK)-cell subsets).

    Time frame: 4 weeks post-treatment

  11. Baseline Prognostic Factors: Number of Prior Therapies

    Relationships between baseline prognostic factors and response may be screened and analyzed quantitatively using logistic regression and adjusting for disease cohort, particularly if a sufficient number of patients respond to this combination therapy.

    Time frame: Baseline

  12. Baseline Prognostic Factors: Tumor Lysis Syndrome (TLS) Risk

    Relationships between baseline prognostic factors and response may be screened and analyzed quantitatively using logistic regression and adjusting for disease cohort, particularly if a sufficient number of patients respond to this combination therapy.

    Time frame: Baseline

  13. Baseline Prognostic Factors: Hemoglobin

    Time frame: Baseline

  14. Baseline Prognostic Factors: Investigations

    Absolute neutrophil count (ANC), Absolute lymphocyte count (ALC) and Platelets.

    Time frame: Baseline

  15. Baseline Prognostic Factor: Beta-2-microglobulin (B2M)

    Beta-2-microglobulin (B2M)

    Time frame: At baseline

  16. Baseline Prognostic Factors: Lactate Dehydrogenase (LDH)

    lactate dehydrogenase (LDH)

    Time frame: At baseline

  17. Baseline Prognostic Factors: Genetic Factors

    Time frame: At baseline

07

Results

Posted Jan 27, 2026

Participant flow

Participant flow — Overall Study
MilestonePhase 1b Cohort 100mg Venetoclax (GDC-0199)Phase 1b Cohort 200mg Venetoclax (GDC-0199)Phase 1b Cohort 400mg Venetoclax (GDC-0199)Phase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment Naïve
Started336252525
Completed336222124
Not completed000341
Withdrew: Adverse event000121
Withdrew: Physician decision000220

Outcome measures

PrimaryMaximum Tolerated Dose of Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib (Phase Ib)
Time frame:
28 days (course 3)
Reported as:
Number · milligrams
Maximum Tolerated Dose of Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib (Phase Ib)
milligramsPhase 1b CohortPhase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment Naïve
Maximum Tolerated Dose of Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib (Phase Ib)400———
PrimaryMinimal Residual Disease (MRD)-Complete Response (CR) Defined by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Criteria (Phase II)

Assessments of MRD will be used in patients classified as CR to further evaluate their status as disease-free and if this further impacts their ability to remain progression-free and alive. MRD will be determined by high sensitivity 4 color flow cytometric analysis of the bone marrow using validated panels.

Time frame:
Up to 8 weeks post-treatment
Reported as:
Number · percentage of participants
Minimal Residual Disease (MRD)-Complete Response (CR) Defined by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Criteria (Phase II)
percentage of participantsPhase 1b CohortPhase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment Naïve
Minimal Residual Disease (MRD)-Complete Response (CR) Defined by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Criteria (Phase II)—445660
SecondaryNumber of Adverse Events Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0

For all patients who receive at least one day of treatment, toxicities will be tabulated by type and grade and displayed in summary form. Serious adverse events are listed with "(SAE)" after the event name.

Time frame:
Up to 4 years
Reported as:
Number · Number of Events
Number of Adverse Events Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
Number of EventsPhase 1b Cohort 100mg Venetoclax (GDC-0199)Phase 1b Cohort 200mg Venetoclax (GDC-0199)Phase 1b Cohort 400mg Venetoclax (GDC-0199)Phase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment Naïve
Abdominal pain5111176
Alanine Aminotransferase Increased248231223
Alkaline Phosphatase Increased20061015
Allergic Reaction100052
Allergic Rhinitis23317243
Alopecia000113
Anemia400202816
Anorexia022102114
Anxiety0131492
Arthralgia4510333719
Arthritis2156121
Aspartate Aminotransferase Increased2311352240
Atrial Fibrillation000245
Back Pain331162213
Blood Bilirubin Increased601244354
Bloating100118
Blurred Vision0048113
Bone Pain002453
Bronchial Infection140732
Bruising3612343330
Bullous Dermatitis210131
Cataract000315
Non-cardiac Chest Pain0011159
Chest Pain - Cardiac001421
Chills110142010
High Cholesterol101741
Chronic Kidney Disease201401
Confusion001032
Conjunctivitis100222
Constipation224243218
Cough224322621
Creatinine Increased778322725
Dental Caries102911
Depression001961
Diarrhea4516464463
Dizziness216111916
Dry Eyes101546
Dry Mouth102131
Dry Skin1031097
Dysgeusia011567
Dyspepsia245294414
Dysphagia000331
Dyspnea1511232514
Ear Pain000254
Epistaxis001117212
Fall00210105
Fatigue41924667639
Fever303151710
Flatulence021102
Floaters001202
Flu Like Symptoms0556621
Flushing001122
Gastroesophageal Reflux Disease014213
Headache566352723
Hearing Impaired000210
Heamaturia100583
Hemorrhoids012121
Hot Flashes000263
Hyperglycemia507534031
Hyperhidrosis474172412
Hyperkalemia210607
Hypernatremia42113133
Hypertension172652225207125
Hyperuricemia6520553728
Hypoalbuminemia01215539
Hypocalcemia31711749856
Hypoglycemia00022218
Hypokalemia310284024
Hypomagnesemia010111412
Hyponatremia100191618
Hypophosphatemia5513191114
Hypothyroidism001131
Infusion Related Reaction364212525
Insomnia156112313
Joint Range of Motion Decreased000112
Leukocytosis200232
Lung Infection022458
Lymph Node Pain110351
Lymphocyte Count Decreased242930170162172
Lymphocyte Count Increased531342231
Malaise000154
Mucositis Oral054254233
Myalgia3113414029
Nail Loss021860
Nasal Congestion223121010
Nausea128324134
Neck Pain120152
Neutrophil Count Decreased183424229169169
Oral Pain001170
Otitis Media000335
Pain406986
Palpitations000747
Paresthesia132152119
Peripheral Sensory Neuropathy013421
Platelet Count Decreased211258177175103
Postnasal Drip1011277
Productive Cough000616
Proteinuria000411
Pruritus110237
Rash Acneiform000353
Rash Maculo-papular214233312
Sinus Bradycardia102362029
Sinus Disorder000611
Sinus Pain000420
Sinus Tachycardia1009510
Sinusitis242352515
Skin Infection10813116
Sleep Apnea012221
Sore Throat013121711
Syncope000221
Testicular Pain201012
Tinnitus000742
Toothache201534
Tremor001014
Upper Respiratory Infection558302811
Urinary Frequency210585
Urinary Tract Infection0026203
Vomiting023191012
White Blood Cell Decreased193424231184186
Weight Gain7136425751
Weight Loss121011108
Activated partial thromboplastin time prolonged201100
Blood and lymphatic system disorders - Other110203
Ear and labyrinth disorders - Other100625
Eye Disorders - Other1106312
Flank Pain100012
Gastrointestinal disorders - Other20214188
Gum Infection200002
Injury, poisoning and procedural complications - Other111191710
Musculoskeletal and connective tissue disorder - Other5461787
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other233292837
Pain in Extremity11222139
Pneumonitis200030
Renal and urinary disorders - Other200110
Skin and subcutaneous tissue disorders - Other4212242329
Surgical and medical procedures - Other100010
Urinary Retention100302
Vascular disorders - Other200111
Atrioventricular block complete010000
Cognitive Disturbance010010
Eye Infection010010
General disorders and administration site conditions - Other010101
Hypertriglyceridemia010001
Infections and infestations - Other013172835
Memory Impairment010010
Metabolism and nutrition disorders - Other012001
Nail Ridging010001
Reproductive system and breast disorders - Other010125
Respiratory, thoracic and mediastinal disorders - Other020120
Rhinitis infective010000
Urinary Urgency010001
Anal Hemorrhage001101
Bladder Spasm001010
Cardiac Disorders - Other001341
Dysarthria003010
Edema Cerebral001000
Edema Face002101
Edema Limbs0029810
Flashing Lights001100
Gastrointestinal Pain001201
Hematoma001004
Hypersomnia002001
Investigations - Other001001
Localized Edema00118158
Osteoporosis001012
Periorbital Edema001000
Rectal Hemorrhage001100
Stomach Pain001110
Tooth Infection001011
Urinary Tract Pain002000
Vaginal Infection001020
Vertigo001002
Cholecystitis000300
Laryngeal inflammation000401
Nail Infection000330
Oral Hemorrhage000220
Otitis Externa000211
Purpura000331
Watering Eyes000200
Fracture000130
Generalized Muscle Weakness000040
Hoarseness000032
Muscle Weakness Lower Limb000130
Agitation000012
Chest Wall Pain000102
Erectile Dysfunction000102
Hiccups000102
INR increased000002
Nervous system disorders - Other000212
Neuralgia000012
Paronychia000522
Blood and lymphatic system disorders - other (SAE)000001
Febrile neutropenia000101
Atrial fibrillation (SAE)000021
Atrioventricular block complete (SAE)010000
Cardiac disorders - Other (SAE)000100
Chest pain - cardiac (SAE)000200
Abdominal pain (SAE)100000
Colitis (SAE)000010
Fatigue (SAE)000110
Fever (SAE)000100
Flu like symptoms (SAE)010000
Cholecystitis (SAE)000100
Bronchial infection (SAE)000100
Infections and infestations - other (SAE)011003
Lung Infection (SAE)011112
Sepsis (SAE)000010
Sinusitis (SAE)000100
Skin infection (SAE)000100
Upper Respiratory Infection (SAE)000100
Infusion related reaction (SAE)000001
Stroke (SAE)000001
Alanine Aminotransferase increased (SAE)000010
Aspartate aminotransferase increased (SAE)000010
Neutrophil count decreased (SAE)000004
Dehydration (SAE)000010
Hyperkalemia (SAE)000002
Hypoglycemia (SAE)000010
Metabolism and nutrition disorders - other (SAE)000001
Tumor lysis syndrome (SAE)000001
Pain in extremity (SAE)000110
Headache (SAE)000100
Nervous system disorders - other (SAE)000110
Syncope (SAE)000100
Pneumonitis (SAE)000010
Wheezing (SAE)000100
Hyperhidrosis (SAE)000001
Hypertension (SAE)010100
SecondaryNumber of Courses Started/Completed

May be summarized.

Time frame:
Up to 14 months
Reported as:
Number · number of subjects
Number of Courses Started/Completed
number of subjectsPhase 1b Cohort 100mg Venetoclax (GDC-0199)Phase 1b Cohort 200mg Venetoclax (GDC-0199)Phase 1b Cohort 400mg Venetoclax (GDC-0199)Phase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment Naïve
Completed 14 cycles336222124
Completed 13 or less cycles000341
SecondaryNumber of Patients Who Reach the Target Dose of Bcl-2 Inhibitor GDC-0199

May be summarized.

Time frame:
Up to 14 months
Reported as:
Count of participants · Participants
Number of Patients Who Reach the Target Dose of Bcl-2 Inhibitor GDC-0199
ParticipantsPhase 1b CohortPhase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment Naïve
Number of Patients Who Reach the Target Dose of Bcl-2 Inhibitor GDC-0199—242525
SecondaryNumber of Patients Requiring Dose Reductions

May be summarized.

Time frame:
Up to 14 months
Reported as:
Count of participants · Participants
Number of Patients Requiring Dose Reductions
ParticipantsPhase 1b Cohort 100mg Venetoclax (GDC-0199)Phase 1b Cohort 200mg Venetoclax (GDC-0199)Phase 1b Cohort 400mg Venetoclax (GDC-0199)Phase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment Naïve
Number of Patients Requiring Dose Reductions000205
SecondaryReason for Going Off Treatment

May be summarized.

Time frame:
Up to 14 months
Reported as:
Number · participants
Reason for Going Off Treatment
participantsPhase 1b Cohort 100mg Venetoclax (GDC-0199)Phase 1b Cohort 200mg Venetoclax (GDC-0199)Phase 1b Cohort 400mg Venetoclax (GDC-0199)Phase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment Naïve
Adverse Event000121
Physician Decision000220
Treatment completed per protocol336222124
SecondaryOverall Response Rate

Overall response rate will be reported for all evaluable patients in the phase II setting, within and potentially across cohorts, assuming a binomial distribution.

Time frame:
Up to 4 years
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsPhase 1b Cohort 100mg Venetoclax (GDC-0199)Phase 1b Cohort 200mg Venetoclax (GDC-0199)Phase 1b Cohort 400mg Venetoclax (GDC-0199)Phase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment Naïve
Overall Response Rate66.7100100888496
SecondaryProgression-free Survival (PFS)

Will be summarized by the Kaplan-Meier method for each of the phase II cohorts.

Time frame:
Time from first treatment date until the date of progression or death, whichever occurs first, assessed up to 8 years
Reported as:
Median · months
Progression-free Survival (PFS)
monthsPhase 1b Cohort 100mg Venetoclax (GDC-0199)Phase 1b Cohort 200mg Venetoclax (GDC-0199)Phase 1b Cohort 400mg Venetoclax (GDC-0199)Phase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment Naïve
Progression-free Survival (PFS)NA (NA to NA)NA (NA to NA)NA (NA to NA)81.8 (57.3 to NA)88.5 (80.6 to NA)NA (NA to NA)
SecondaryEmotional Distress Assessment

Validated instruments will be administered serially to assess longitudinal changes in measures of health related quality of life using 36-Item Short Form Survey (SF-36) Mental Component Scale (MCS) T-scores for each time point with pairwise comparison p-values. Scores on the SF-36 scale range from 0 to 100, with higher scores indicating better mental health. Scores for the MCS are standardized using U.S. general population norms with summary scores set relative to a t-score mean of 50 and a standard deviation of 10.

Time frame:
Cycle 1 day 1, cycle 2 day 1, cycle 3 day 1, cycle 6 day 1 and cycle 12 day 1
Reported as:
Mean · T-score
Emotional Distress Assessment
T-scorePhase 1b Cohort 100mg Venetoclax (GDC-0199)Phase 1b Cohort 200mg Venetoclax (GDC-0199)Phase 1b Cohort 400mg Venetoclax (GDC-0199)Phase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment Naïve
Cycle 1 Day 1———54.03 ± 9.2552.32 ± 6.87—
Cycle 2 Day 1———54.42 ± 7.7554.88 ± 6.10—
Cycle 3 Day 1———55.90 ± 7.0554.33 ± 6.54—
Cycle 6 Day 1———56.31 ± 7.6453.50 ± 8.96—
Cycle 12 Day 1———55.53 ± 5.3454.35 ± 6.30—
SecondaryHealth Related Quality of Life

Validated instruments will be administered serially to assess longitudinal changes in measures of health related quality of life using 36-Item Short Form Survey (SF-36) Physical Component Scale (PCS) T-scores for each time point with pairwise comparison p-values. Scores on the SF-36 scale range from 0 to 100, with higher scores indicating better physical health. Scores for the PCS are standardized using U.S. general population norms with summary scores set relative to a t-score mean of 50 and a standard deviation of 10.

Time frame:
Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 6 Day 1, and Cycle 12 Day 1 (each cycle is 28 days)
Reported as:
Mean · T-score
Health Related Quality of Life
T-scorePhase 1b CohortPhase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment Naïve
Cycle 1 Day 1—42.88 ± 12.5244.25 ± 10.97—
Cycle 2 Day 1—45.53 ± 12.1242.01 ± 10.57—
Cycle 3 Day 1—45.17 ± 13.5644.92 ± 11.86—
Cycle 6 Day 1—45.94 ± 12.9546.75 ± 11.37—
Cycle 12 Day 1—45.97 ± 14.0546.40 ± 11.45—
SecondarySerial Assessment of Immune Effector Cell Number and Function.

Peripheral blood immunophenotyping will be used to enumerate immune effector cells (counts and percentages of T-, and Natural Killer (NK)-cell subsets).

Time frame:
4 weeks post-treatment
Reported as:
Mean · 10^3 cells/uL
Serial Assessment of Immune Effector Cell Number and Function.
10^3 cells/uLPhase 1b CohortPhase 2 Relapsed/Refractory (RR)TN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment Naïve
NK—95 ± 6489 ± 49—
CD3+CD4+—499 ± 217738 ± 298—
CD3+CD8+—479 ± 296312 ± 213—
SecondaryBaseline Prognostic Factors: Number of Prior Therapies

Relationships between baseline prognostic factors and response may be screened and analyzed quantitatively using logistic regression and adjusting for disease cohort, particularly if a sufficient number of patients respond to this combination therapy.

Time frame:
Baseline
Reported as:
Median · Number of Prior Therapies
Baseline Prognostic Factors: Number of Prior Therapies
Number of Prior TherapiesPhase 1b Cohort 100mg Venetoclax (GDC-0199)Phase 1b Cohort 200mg Venetoclax (GDC-0199)Phase 1b Cohort 400mg Venetoclax (GDC-0199)Phase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment Naïve
Baseline Prognostic Factors: Number of Prior Therapies1 (1 to 7)1 (1 to 2)1 (1 to 2)1 (1 to 3)0 (0 to 0)0 (0 to 0)
SecondaryBaseline Prognostic Factors: Tumor Lysis Syndrome (TLS) Risk

Relationships between baseline prognostic factors and response may be screened and analyzed quantitatively using logistic regression and adjusting for disease cohort, particularly if a sufficient number of patients respond to this combination therapy.

Time frame:
Baseline
Reported as:
Number · participants
Baseline Prognostic Factors: Tumor Lysis Syndrome (TLS) Risk
participantsPhase 1b Cohort 100mg Venetoclax (GDC-0199)Phase 1b Cohort 200mg Venetoclax (GDC-0199)Phase 1b Cohort 400mg Venetoclax (GDC-0199)Phase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment Naïve
TLS Risk Low001711
TLS Risk Medium23281817
TLS Risk High1031067
SecondaryBaseline Prognostic Factors: Hemoglobin
Time frame:
Baseline
Reported as:
Median · grams per deciliter
Baseline Prognostic Factors: Hemoglobin
grams per deciliterPhase 1b Cohort 100mg Venetoclax (GDC-0199)Phase 1b Cohort 200mg Venetoclax (GDC-0199)Phase 1b Cohort 400mg Venetoclax (GDC-0199)Phase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment Naïve
Baseline Prognostic Factors: Hemoglobin12.3 (12.3 to 13.3)11.4 (11.2 to 12.7)12.7 (11.6 to 15.8)12 (9 to 16)10 (8 to 13)10 (7 to 15)
SecondaryBaseline Prognostic Factors: Investigations

Absolute neutrophil count (ANC), Absolute lymphocyte count (ALC) and Platelets.

Time frame:
Baseline
Reported as:
Median · 10^3 cells/uL
Baseline Prognostic Factors: Investigations
10^3 cells/uLPhase 1b Cohort 100mg Venetoclax (GDC-0199)Phase 1b Cohort 200mg Venetoclax (GDC-0199)Phase 1b Cohort 400mg Venetoclax (GDC-0199)Phase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment Naïve
Platelets117 (103 to 227)158 (102 to 208)171.5 (139 to 222)132 (52 to 255)166 (68 to 231)132 (23 to 488)
ANC8.9 (0.2 to 23.5)2.6 (0 to 5.1)5.5 (3.2 to 9.9)3 (1 to 28)5 (1 to 26)4 (1 to 16)
ALC135.3 (19.6 to 445.6)144.9 (79.2 to 230.6)30.0 (2.8 to 287.2)29 (0 to 348)109 (3 to 413)191 (3 to 488)
SecondaryBaseline Prognostic Factor: Beta-2-microglobulin (B2M)

Beta-2-microglobulin (B2M)

Time frame:
At baseline
Reported as:
Median · milligrams per liter
Baseline Prognostic Factor: Beta-2-microglobulin (B2M)
milligrams per literPhase 1b Cohort 100mg Venetoclax (GDC-0199)Phase 1b Cohort 200mg Venetoclax (GDC-0199)Phase 1b Cohort 400mg Venetoclax (GDC-0199)Phase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment Naïve
Baseline Prognostic Factor: Beta-2-microglobulin (B2M)5.2 (3.9 to 6.8)4.2 (2.7 to 5.0)2.6 (2.2 to 3.4)4 (2 to 7)3 (2 to 7)3 (2 to 6)
SecondaryBaseline Prognostic Factors: Lactate Dehydrogenase (LDH)

lactate dehydrogenase (LDH)

Time frame:
At baseline
Reported as:
Median · units per liter
Baseline Prognostic Factors: Lactate Dehydrogenase (LDH)
units per literPhase 1b Cohort 100mg Venetoclax (GDC-0199)Phase 1b Cohort 200mg Venetoclax (GDC-0199)Phase 1b Cohort 400mg Venetoclax (GDC-0199)Phase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment Naïve
Baseline Prognostic Factors: Lactate Dehydrogenase (LDH)293 (219 to 371)301 (237 to 410)202 (155 to 899)223 (131 to 725)230 (98 to 710)280 (147 to 921)
SecondaryBaseline Prognostic Factors: Genetic Factors
Time frame:
At baseline
Reported as:
Number · participants
Baseline Prognostic Factors: Genetic Factors
participantsPhase 1b Cohort 100mg Venetoclax (GDC-0199)Phase 1b Cohort 200mg Venetoclax (GDC-0199)Phase 1b Cohort 400mg Venetoclax (GDC-0199)Phase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment Naïve
High Hyperdiploid (HeH)———191719
Zap-70 methylated0141183
Complex karyotype1138811
del(17p)001132
del(11q)314957
trisomy 12001433
del(13q)2020516

Adverse events

Collected over Up to 4 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1b Cohort 100mg Venetoclax (GDC-0199)1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Phase 1b Cohort 200mg Venetoclax (GDC-0199)0/3 (0%)3/3 (100%)3/3 (100%)
Phase 1b Cohort 400mg Venetoclax (GDC-0199)0/6 (0%)2/6 (33.3%)6/6 (100%)
Phase 2 Relapsed/Refractory1/25 (4%)12/25 (48%)25/25 (100%)
TN1: Phase 2 Treatment Naïve1/25 (4%)7/25 (28%)25/25 (100%)
TN2: Phase 2 Treatment Naïve1/25 (4%)11/25 (44%)25/25 (100%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventPhase 1b Cohort 100mg Venetoclax (GDC-0199)Phase 1b Cohort 200mg Venetoclax (GDC-0199)Phase 1b Cohort 400mg Venetoclax (GDC-0199)Phase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment Naïve
Abdominal painGastrointestinal disorders1/30/30/60/250/250/25
Atrioventricular block completeCardiac disorders0/31/30/60/250/250/25
Flu like symptomsGeneral disorders0/31/30/60/250/250/25
HypertensionVascular disorders0/31/30/61/250/250/25
Infections and infestations - OtherInfections and infestations0/31/31/60/250/253/25
Lung infectionInfections and infestations0/31/31/61/251/252/25
Neutrophil count decreasedInvestigations0/30/30/60/250/254/25
Chest pain - cardiacCardiac disorders0/30/30/62/250/250/25
Upper respiratory infectionInfections and infestations0/30/30/62/250/250/25
Atrial fibrillationCardiac disorders0/30/30/60/252/251/25
Most frequent other events
Showing 10 of 191
Most frequent other events
EventPhase 1b Cohort 100mg Venetoclax (GDC-0199)Phase 1b Cohort 200mg Venetoclax (GDC-0199)Phase 1b Cohort 400mg Venetoclax (GDC-0199)Phase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment Naïve
Alanine Aminotransferase increasedInvestigations2/33/34/610/258/2513/25
Allergic RhinitisRespiratory, thoracic and mediastinal disorders1/33/33/613/2515/253/25
ArthralgiaMusculoskeletal and connective tissue disorders3/31/35/613/2517/259/25
Aspartate Aminotransferase IncreasedInvestigations2/33/33/613/2512/2517/25
BruisingInjury, poisoning and procedural complications3/33/36/620/2519/2519/25
DiarrheaGastrointestinal disorders2/32/36/619/2517/2524/25
FatigueGeneral disorders3/32/36/621/2523/2517/25
HyperglycemiaMetabolism and nutrition disorders3/30/35/616/2518/2514/25
HyperhidrosisSkin and subcutaneous tissue disorders3/33/32/610/2512/257/25
HypertensionVascular disorders3/33/36/625/2525/2522/25

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Phase 1b Cohort 100mg Venetoclax (GDC-0199)Phase 1b Cohort 200mg Venetoclax (GDC-0199)Phase 1b Cohort 400mg Venetoclax (GDC-0199)Phase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment NaïveTotal
<=18 years0000000
Between 18 and 65 years22619182067
>=65 years11067520
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1b Cohort 100mg Venetoclax (GDC-0199)Phase 1b Cohort 200mg Venetoclax (GDC-0199)Phase 1b Cohort 400mg Venetoclax (GDC-0199)Phase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment NaïveTotal
Female001910828
Male33516151759
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1b Cohort 100mg Venetoclax (GDC-0199)Phase 1b Cohort 200mg Venetoclax (GDC-0199)Phase 1b Cohort 400mg Venetoclax (GDC-0199)Phase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment NaïveTotal
Hispanic or Latino0000101
Not Hispanic or Latino33625242384
Unknown or Not Reported0000022
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1b Cohort 100mg Venetoclax (GDC-0199)Phase 1b Cohort 200mg Venetoclax (GDC-0199)Phase 1b Cohort 400mg Venetoclax (GDC-0199)Phase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment NaïveTotal
American Indian or Alaska Native0000000
Asian0001001
Native Hawaiian or Other Pacific Islander0000000
Black or African American0001012
White33623252282
More than one race0000000
Unknown or Not Reported0000022
Region of Enrollment
Region of Enrollment(participants)Phase 1b Cohort 100mg Venetoclax (GDC-0199)Phase 1b Cohort 200mg Venetoclax (GDC-0199)Phase 1b Cohort 400mg Venetoclax (GDC-0199)Phase 2 Relapsed/RefractoryTN1: Phase 2 Treatment NaïveTN2: Phase 2 Treatment NaïveTotal
United States33625252587
08

Study locations

1 site
09

References and documents

Publications

  • Arrato NA, Valentine TR, Byrd JC, Jones JA, Maddocks KJ, Woyach JA, Andersen BL. Illness representations and psychological outcomes in chronic lymphocytic leukaemia. Br J Health Psychol. 2022 May;27(2):553-570. doi: 10.1111/bjhp.12562. Epub 2021 Oct 4. PubMed 34608724 ↗
  • Rogers KA, Huang Y, Ruppert AS, Abruzzo LV, Andersen BL, Awan FT, Bhat SA, Dean A, Lucas M, Banks C, Grantier C, Heerema NA, Lozanski G, Maddocks KJ, Valentine TR, Weiss DM, Jones JA, Woyach JA, Byrd JC. Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol. 2020 Nov 1;38(31):3626-3637. doi: 10.1200/JCO.20.00491. Epub 2020 Aug 14. PubMed 32795224 ↗
  • Rogers KA, Huang Y, Ruppert AS, Awan FT, Heerema NA, Hoffman C, Lozanski G, Maddocks KJ, Moran ME, Reid MA, Lucas M, Woyach JA, Whitlow WT, Jones JA, Byrd JC. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. Blood. 2018 Oct 11;132(15):1568-1572. doi: 10.1182/blood-2018-05-853564. Epub 2018 Aug 15. PubMed 30111609 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Dec 2021, 76 months.

Results were first posted in Jan 2026, 4 years 1 month after primary completion.

Of 40 non-industry phase 1/2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 53 and three quarters within 103. This study's 76 months is close to that.

Counting every sponsor, half of 90 studies reached it within 78 months; a quarter within 51 and three quarters within 103.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2015
First posted
Apr 28, 2015
StartActual
Aug 3, 2015
Primary completionActual
Dec 24, 2021
CompletionEst.
Apr 15, 2027
Results first posted
Jan 27, 2026
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02427451
Lead sponsor
Kerry Rogers
Responsible party
Kerry Rogers (Principal Investigator, Ohio State University Comprehensive Cancer Center) — Sponsor-investigator
First posted
Apr 28, 2015
Start date
Aug 3, 2015
Primary completion
Dec 24, 2021
Completion
Apr 15, 2027 (estimated)
Results posted
Jan 27, 2026
Last update
Jun 15, 2026

Study contacts

Kerry Rogers, MD
principal investigator · Ohio State University Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion